Inhalon Biopharma, Inc.

NIH SBIR/STTR award: Development of IN-003PI as passive immunization against human metapneumovirus infection

USD 1,013,468.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

NIH SBIR/STTR award: IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A

USD 1,013,003.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

NIH SBIR/STTR award: Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV

USD 1,024,945.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

NIH SBIR/STTR award: IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection

USD 1,024,879.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

NIH SBIR/STTR award: SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections

USD 1,023,875.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

NIH SBIR/STTR award: GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus

USD 608,832.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)